Three finalists named for the EUROPEAN BIOTECHNICA AWARD 2006

BIOTECHNICAThe three finalists of the EUROPEAN BIOTECHNICA AWARD 2006 have been announced. The international jury of nine experts has nominated biotechnology companies from Germany, Austria and Denmark for the Award, which is worth a total of 40,000 euros in prize money. The jury selected the finalists from a field of 16 outstanding candidates from eight countries.

The following companies – listed below in alphabetical order – will be travelling to Zurich for the grand finale on 12 October 2006:

  • amaxa GmbH, Cologne/Germany
    Founded in 1998, the biotech company amaxa develops and markets innovative products for non-viral gene transfer, enabling researchers to efficiently deliver DNA or siRNA into cells to elucidate the function of genes. amaxa currently employs a workforce of 145 and generated sales of 16.6 million euros in 2005. In addition to its headquarters in Cologne, amaxa also operates a facility in Gaithersburg/USA.
  • Genmab A/S, Copenhagen/Denmark
    The Danish biotech company Genmab specializes in the production and development of human antibodies for the treatment of life-threatening and debilitating cancers and infectious diseases. Employing a staff of 220, the company reported sales of 13.2 million euros in 2005. In addition to its main production facility in Copenhagen, Genmab also has operations in Utrecht/Netherlands, Hitchin/UK and Princeton/USA.
  • Intercell AG, Vienna/Austria
    Founded in Vienna in 1998, Intercell is a biotechnology company focused on the development of innovative vaccines for the prevention and treatment of infectious diseases. The company currently employs 160 people, and posted sales of 8.5 million euros in 2005. Intercell also has a manufacturing facility in Livingston/Scotland and a business development unit in Mooresville/USA.

The award ceremony for the EUROPEAN BIOTECHNICA AWARD 2006 takes place on 12 October 2006. The proceedings begin at 5.30 p.m., immediately following the Biotech CEO Conference hosted by the German Stock Exchange and DZ BANK AG in the Park Hyatt Hotel in Zurich.

Before the official presentation of prizes a series of distinguished speakers will take to the podium to talk about future directions in biotechnology and the life sciences. The line-up is as follows: Dr. Annette Schavan, Federal Minister for Education and Research, Berlin; Dr. Peter Hug, a member of the Executive Committee of F. Hoffmann-La Roche AG, Basel; Jörn Aldag, Chairman of the Board of Evotec AG, Hamburg; and Dr. Hans-Jürgen Leuchs, a member of the Board of Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim. The jury chairman Prof. Dr. Peter Stadler will then deliver the eulogy and present the prizes to the winners of the EUROPEAN BIOTECHNICA AWARD 2006.

"The EUROPEAN BIOTECHNICA AWARD is Europe's most important and valuable prize for small and medium-sized enterprises working in biotechnology and the life sciences," explains Stephan Ph. Kühne, a member of the Board at Deutsche Messe AG in Hannover, which organizes the annual Award. "With the prize award ceremony, talks by guest speakers and an informal get-together for all participants, the event creates the perfect business platform for biotech professionals to network and make valuable contacts," Kühne adds.

The event package accompanying the presentation of the 4th EUROPEAN BIOTECHNICA AWARD highlights the latest industry trends emerging from the collaboration between the major pharmaceutical players and innovative biotechnology companies. "The keynote addresses are sure to stimulate plenty of lively debate at the informal get-together afterwards," Kühne predicts.

One of the chief aims underlying the annual EUROPEAN BIOTECHNICA AWARD and the biennial international trade fair BIOTECHNICA is to promote the formation of effective biotech networks. The next BIOTECHNICA show will take place from 9 to 11 October 2007, when business enterprises and research organizations working in this field will meet again in Hannover to share information and compare notes.

Your contact for further information:
Inga Waldeck
Tel.: +49 (0) 511/89-3 10 26
Fax: +49 (0) 511/89-3 96 95
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

For further information, please visit:
www.biotechnica.de

Most Popular Now

AI Points the Way to Better Doctor-Patie…

A computer analysis of hundreds of thousands of secure email messages between doctors and patients found that most doctors use language that is too complex for their patients to understand...

Open Call DIGITAL-2021-DEPLOY-01-TWINS-H…

The development of digital twins in healthcare (DTH) has progressed substantially, profiting from advances in science and technology. In order to exploit their benefits in view of better prevention approaches...

Mayo Clinic Researchers Use AI, Biomarke…

Treatment options for rheumatoid arthritis have often relied on trial and error. Now Mayo Clinic researchers are exploring the use of artificial intelligence (AI) and pharmacogenomics to predict how patients...

Mjog by Livi Launches Remote Monitoring …

Mjog by Livi has launched a remote monitoring tool that will help GPs support and monitor people with depression through messages sent to their smartphones. The latest data from the Office...

Could EKGs Help Doctors use AI to Detect…

Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI)...

Computer Model of Blood Enzyme

Membrane-associated proteins play a vital role in a variety of cellular processes, yet little is known about the membrane-association mechanism. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is one such protein with an...

4.5 Million Euros in EU Funding for Saar…

This year, three computer scientists from Saarbrücken were awarded an "ERC Starting Grant" by the European Research Council. This award, endowed with 1.5 million euros each, is among the most...

2022 EU4Health Work Programme Adopted to…

Today the Commission has adopted the second EU4Health work programme. In 2022, the EU4Health will continue to invest in building stronger, more resilient health systems and pave the way for...

Five NHS Trusts in Surrey and Sussex to …

A consortium of NHS trusts that covers a population of circa 1.2 million will gain immediate access to important patient imaging, and will mobilise a regional workforce for patients, following...

Helping Cancer Patients Avoid Excessive …

A Case Western Reserve University-led team of scientists has used Artificial Intelligence (AI) to identify which patients with certain head and neck cancers would benefit from reducing the intensity of...

The Programme for the Union's Action in …

On 24 March 2021, Regulation (EU) 2021/522 of the European Parliament and of the Council1 was adopted as part of the Multiannual Financial Framework for the 2021-2027 period. That Regulation...

CliniSys Acquires HORIZON Lab Systems an…

CliniSys is announcing the recent acquisition of HORIZON Lab Systems and the combination with Sunquest Information Systems, as CliniSys. This acquisition and Sunquest combination creates one of the world’s...